Article

Several studies to provide new information, data about olopatadine

Four studies about olopatadine hydrochloride ophthalmic solution 0.1%(Patanol, Alcon Laboratories) and olopatadine hydrochloride ophthalmic solution0.2% (Patanol once-a-day) will be presented at ARVO, Alcon Laboratoriesannounced.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
Related Content
Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)
January 13th 2025

Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Multiple companies appoint new leadership across the industry
January 13th 2025

Multiple companies appoint new leadership across the industry

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

New research links retinal imaging and deep learning to improved schizophrenia detection
January 11th 2025

New research links retinal imaging and deep learning to improved schizophrenia detection

Eyebright Medical receives Class III Certificate from National Medical Products Administration in China for its phakic intraocular lens
January 11th 2025

Eyebright Medical receives Class III Certificate from National Medical Products Administration in China for its phakic intraocular lens

© 2025 MJH Life Sciences

All rights reserved.